Table 1 Sociodemographic, treatment and immunity characteristics of study participants
Variables | Cryptosporidium spp | Isospora belli | ||
|---|---|---|---|---|
Yes | No | Yes | No | |
Age (mean, ±1SD) (n = 268) | 33.5, ±8.1 | 34.3, ±8.5 | 35.5, ±5.5 | 34.0, ±8.3 |
CD4 count (n = 268) | ||||
≤ 250 | 67 (35.8) | 120 (64.2) | 3 (1.6) | 184 (98.4) |
251-350 | 14 (29.8) | 33 (70.2) | 1 (2.1) | 46 (97.9) |
≥ 351 | 11 (32.4) | 23 (67.6) | 0 (0.0) | 34 (100.0) |
Sex (male: female) (n = 268) | 0.74:1 | 0.96:1 | 1:01 | 0.870;1 |
Treatment status (n = 268) | ||||
On HAART | 38 (28.4) | 96 (71.6) | 1 (0.8) | 133 (99.2) |
Not on HAART | 54 (40.3) | 80 (59.7) | 3 (2.2) | 131 (97.8) |
HAART regimen (n = 134) | ||||
D4T/3TC/NVP | 20 (23.5) | 65 (76.5) | 1 (1.2) | 84 (98.8) |
D4T/3TC/EFV | 2 (28.6) | 5 (71.4) | 0 (0.0) | 7 (100.0) |
AZT/3TC/NVP | 15 (41.7) | 21 (58.3) | 0 (0.0) | 36 (100.0) |
AZT/3TC/EFV | 1 (16.7) | 5 (83.3) | 0 (0.0) | 6 (100.0) |
Duration on HAART (in months) (n = 134) | ||||
(n = 134, mean, ± 1SD) | 8.9, ± 4.0 | 10.1 ± 5.9 | 9.4 ± 5.4 | 4.0* |
2-7 months | 14 (28.6) | 35 (71.4) | ||
> = 8 months | 24 (28.2) | 61 (71.8) | ||